---
id: 076
title: Hepatitis C Direct-Acting Antivirals (DAAs)
category: antimicrobials
subcategory: antivirals_hcv
tags: [HCV, DAAs, sofosbuvir, ledipasvir, glecaprevir-pibrentasvir, SVR]
difficulty: medium
---

## Question

What are the major HCV DAA classes and modern regimens? Use the **"NS5A-NS5B-NS3/4A = SVR >95%"** mnemonic.

## Answer

### **"NS5A-NS5B-NS3/4A = SVR >95%" Mnemonic:**

**NS5A Inhibitors:** Ledipasvir, velpatasvir, pibrentasvir
**NS5B Inhibitors:** **Sofosbuvir** (nucleotide polymerase inhibitor - backbone of most regimens)
**NS3/4A Inhibitors:** Glecaprevir, grazoprevir (protease inhibitors)

**SVR >95%:** Sustained virologic response (cure rate) >95% with modern DAAs

### **Modern Single-Tablet Regimens (2024):**

| Regimen | Components | Duration | Genotypes |
|---------|------------|----------|-----------|
| **Sofosbuvir/velpatasvir** (Epclusa) | NS5B + NS5A | **12 weeks** | **Pan-genotypic (1-6)** |
| **Glecaprevir/pibrentasvir** (Mavyret) | NS3/4A + NS5A | **8-12 weeks** | **Pan-genotypic (1-6)** |
| **Ledipasvir/sofosbuvir** (Harvoni) | NS5A + NS5B | 12 weeks | Genotype 1, 4-6 |

**Preferred:** Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir (pan-genotypic, short duration)

## Key Points

### **Treatment Goals:**
- **SVR12:** Undetectable HCV RNA 12 weeks after treatment completion = **CURE**
- Modern regimens: **>95% SVR** across all genotypes

### **Advantages of DAAs:**
- **Short duration** (8-12 weeks vs 24-48 weeks with interferon)
- **Minimal side effects** (vs interferon)
- **Pan-genotypic** (no genotype testing needed for some regimens)
- **Oral therapy** (single tablet daily)
- **No interferon/ribavirin** needed

### **Key Considerations:**
- **Drug interactions:** Check with **HepCdrug interactions.org**
- **Renal impairment:** Sofosbuvir contraindicated if GFR <30 (use glecaprevir/pibrentasvir)
- **Cirrhosis:** May extend to 24 weeks if decompensated
- **Resistance testing:** Generally not needed (high SVR rates)

### **Clinical Pearls:**
- **Cure rate >95%** with modern DAAs
- **8-12 week regimens** standard
- **Pan-genotypic regimens** simplify treatment (no genotyping needed)
- **Drug interactions critical** to check (especially with HIV ARVs)
- **SVR = functional cure** (risk of HCC remains if cirrhosis present)

## Sources

- [AASLD-IDSA HCV Guidance 2024]
- [WHO: Updated Recommendations on HCV Treatment]

## Media

N/A
